LOTTE BIOLOGICS to Join a Series of Global Biopharma Events in the Second Half of 2025
Strengthening CDMO Market Competitiveness

■  Participation in major global biopharma conferences including BIO Japan 2025, CPhI Worldwide, and World ADC San Diego 2025
■  Expanding global partnerships across Asia, Europe, and the United States to reinforce market competitiveness
■  CEO James Park to speak on Day 3 of BIO Japan 2025; additional presentations from LOTTE BIOLOGICS leaders at CPhI Worldwide and World ADC

▲ [Photo] LOTTE BIOLOGICS’ exhibition booth at CPhI Worldwide.

Seoul, South Korea — September 22, 2025 — LOTTE BIOLOGICS (CEO James Park) announced today that it will participate in a series of international biopharma conferences across Asia, Europe, and the United States from October through November, showcasing its competitiveness as a global CDMO.

The company’s schedule begins with BIO Japan 2025 (October 8–10, Yokohama), followed by CPhI Worldwide (October 28–30, Frankfurt), and World ADC San Diego 2025 (November 3–6, San Diego).

LOTTE BIOLOGICS will leverage two strategic pillars, its Dual Site Advantage (Syracuse and Songdo) and proven quality excellence, to reinforce global partnerships. The Syracuse Bio Campus has already secured three contracts this year, while the first plant at the Songdo Bio Campus, scheduled to commence operations in 2027, recently held its topping-out ceremony on September 9, further demonstrating the company’s growing dual-site strength. In line with the reshoring trend in the U.S. biomanufacturing industry, the company also plans to emphasize its role as an optimal partner in addressing global supply chain uncertainties.

BIO Japan, established in 1986, is the largest biopharma partnering event in Asia, supporting exhibitions, seminars, and partnering programs. This year, LOTTE BIOLOGICS will host a booth more than double the size of last year’s, hosting company presentations and partnering meetings. On October 10 (Day 3), CEO James Park will serve as a seminar speaker, delivering a presentation titled “Pharma's Next Frontier: CDMO Strategies and the Growing Market for Next-Gen ADCs”, highlighting the company’s CDMO strategy and market competitiveness.

At CPhI Worldwide, the world’s largest annual pharmaceutical exhibition, LOTTE BIOLOGICS will host an in-booth presentation spotlighting its ADC manufacturing capabilities at the Syracuse Bio Campus and the synergies with the upcoming Songdo Bio Campus. The booth will also feature interactive activities, to further engage visitors and potential partners.

In November, LOTTE BIOLOGICS will join global pharma companies and industry experts at World ADC San Diego 2025, one of the world’s most preeminent ADC-focused events, to share the latest research and technological advancements. During the sessions, the company will highlight the strengths of its ADC platform and emphasize its proven competitiveness as a global ADC CDMO. On November 3, Kern Chang will again take the stage as a speaker.

LOTTE BIOLOGICS has been consistently expanding its presence through participation in global conferences.  Earlier this year it attended the J.P. Morgan Healthcare Conference, World ADC Asia, and BIO USA, among others. At BIO USA in June, the company announced a new antibody therapeutics manufacturing contract with a global biopharma company, further solidifying its position as a global CDMO.

A LOTTE BIOLOGICS spokesperson stated, “We will actively showcase LOTTE BIOLOGICS’ proven capabilities at these international events. In the second half of the year, we will continue to strengthen our global competitiveness through active partnering.”